NA+8 (previously NAD8) (Inner Vita Pty Ltd)
Product Name
NA+8 (previously NAD8)
Sponsor
ARTG details
Date of review outcome
Date of publication
Sep-2026
Outcome
Medicine continues to be permitted for supply. Batches released from 1 May 2026 must carry a corrected label.
Is it safe to continue using this medicine?
Yes, based on the sponsor's certification. However, use of this medicine may pose a safety risk for some people. Follow the recommended actions below.
What action should consumers take?
In rare cases, Camellia sinensis may harm the liver. Stop use and see a doctor if you have yellowing skin/eyes, or unusual: fatigue, nausea, appetite loss, abdominal pain, dark urine, or itching. If pregnant or likely to become pregnant, consult a pharmacist or a doctor before use.
Consider whether this medicine is right for you given that claims including to boost and regenerate natural energy and providing cellular integrity and healthy aging were not substantiated by the sponsor.
Be aware this medicine does not contain the ingredient NAD as implied by its name.
Consider whether this medicine is right for you given that claims including to boost and regenerate natural energy and providing cellular integrity and healthy aging were not substantiated by the sponsor.
Be aware this medicine does not contain the ingredient NAD as implied by its name.
Review scope
Targeted (see Additional Information below)
Information reviewed
ARTG Record, Labels, Manufacturing Documentation, Website
Issues related to safety
The label for this medicine included incorrect versions of or was missing the mandatory warning statements for the ingredients Camellia sinensis and nicotinic acid, as set out under 'What action should consumers take?' These warning statements are necessary to ensure the safe use of this medicine and to alert consumers to safety risks prior to taking it.
While these omissions are unacceptable, current data indicates this medicine is unlikely to pose an immediate risk to consumer health and safety.
While these omissions are unacceptable, current data indicates this medicine is unlikely to pose an immediate risk to consumer health and safety.
Issues related to efficacy
This medicine does not contain the ingredient NAD as implied by its name. Therefore, it may not work for claims related to NAD.
The label and website for this medicine contained claims specified in 'What action should consumers take?' above. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
The label and website for this medicine contained claims specified in 'What action should consumers take?' above. However, these claims were not covered by the sponsor's certification that they held evidence to substantiate them.
Actions taken during the review
The TGA required the sponsor to correct the issues with this medicine. The sponsor updated the ARTG record, label and website to correct the issues with this medicine. As the affected batch was largely supplied in China, the relevant Chinese authority has been notified of this matter.
Additional information
This medicine was targeted to check its compliance in relation to claims about nicotinamide adenine dinucleotide (NAD, NAD+, NADH) or nicotinamide mononucleotide (NMN)